ASSOCIATION BETWEEN OXIDATIVE STRESS AND MELANOMA PROGRESSION

Jelena Pantic Bisevac,1 Mirjana Djukic,2 Ivan Stanojevic,3,4 Ivana Stevanovic,5 Zeljko Mijuskovic,4,5 Ana Djuric,2 Borko Gobeljic,2 Tatjana Banovic,6 Danilo Vojvodic,3,4

1Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia
2Department of Toxicology, Faculty of Pharmacy, University of Belgrade, Serbia
3Institute for Medical Research, Military Medical Academy, Belgrade, Serbia
4Medical Faculty, University of Defense, Ministry of Defense, Belgrade, Serbia
5Clinic of Dermatology, Military Medical Academy, Belgrade, Serbia
6Department of Immunology, SA Pathology, Royal Adelaide Hospital, Adelaide, Australia

Summary

Background: Overproduction of free radicals accompanied with their insufficient removal/neutralization by antioxidative defense system impairs redox hemostasis in living organisms. Oxidative stress has been shown to be involved in all the stages of carcinogenesis and malignant melanocyte transformation. The aim of this study was to examine association between oxidative stress development and different stages of melanoma.

Methods: The measured oxidative stress parameters included: superoxide anion radical, total and manganese superoxide dismutase, catalase and malondialdehyde. Oxidative stress parameters were measured spectrophotometrically in serum samples from melanoma patients (n=72) and healthy control subjects (n=30). Patients were classified according to AJCC clinical stage.

Results: Average superoxide anion and malondialdehyde concentrations were significantly higher in melanoma patients than in control group, with the highest value of superoxide anion in stage III, while malondialdehyde highest value was in stage IV. The activity of total and manganese superoxide dismutase was insignificantly higher in melanoma patients than in control group, while catalase activity was significantly higher. The highest activity of total

List of abbreviations: ADS, antioxidative defense system; AJCC, American Joint Committee on Cancer; C, control group; CAT, catalase; FRs, free radicals; LPO, lipid peroxidation; MDA, malondialdehyde; Mn-SOD, manganese superoxide dismutase; NBT, nitroblue-tetrazolium; NF-κB, nuclear factor kappa B; O2•−, superoxide anion radical; OS, oxidative stress; PUFA, poly unsaturated fatty acids; ROS, reactive oxygen species; rpm, revolutions per minute; TMP, total melanoma patients; tSOD, total superoxide dismutase; WHO, World Health Organization.
superoxide dismutase was in stage III, while the highest activity of manganese superoxide dismutase was in stage IV. Catalase activity was increasing with the disease progression achieving the maximum in stage III.

**Conclusions:** Results of our study suggest that melanoma is oxidative stress associated disease, as well as deteriorated cell functioning at mitochondrial level.

**Keywords:** antioxidants, free radicals, melanoma, oxidative stress

---

**Introduction**

World Health Organization classified melanoma into four common types: superficial spreading, nodular, lentigo maligna and acral lentiginous; and six less frequent (1). Although melanoma accounts for only 4% of all skin cancers, it causes the greatest number of skin cancer related deaths worldwide (2). It also affects other extra-cutaneous pigment-containing sites including eyes, meninges, esophagus and mucous membranes. Cutaneous melanoma is the most common and aggressive subtypes of melanoma, arising from malignant transformation of epidermal melanocytes (3), while mucosal melanoma arising from mucous membranes melanocytes and uveal melanoma from ocular stroma melanocytes (4). Melanoma is characterized by high invasion and metastasis capacity and remarkable genotypic and phenotypic heterogeneity (5). It is located mostly on the back of male and legs of female. Melanoma usually affects Caucasian in the fourth life decade. Men found to be more vulnerable to melanoma than women (6). Melanoma risk factors include pale skin, blond or red hair, numerous freckles and tendency to burn and tan poorly (7, 8), existence of more than 50 acquired naevi (9) or 5 dysplastic naevi, large congenital nevi (10), chemical exposures, immunosuppression, genetic factors, scars etc.

Malignant melanocyte transformation has been recognized to be associated with oxidative stress (OS) (11). Redox homeostasis impairment in living organisms is consequence of free radicals (FRs) overproduction and/or insufficient antioxidative defense. Oxidative injuries of biomolecules (including DNA, proteins and lipids) disrupt cell’s signalization, devastate reduction equivalent cell sources and energy and usually culminate with cell death (apoptosis). Noteworthy, changed cell signalization can trigger disease development.

Cell mitochondrial respiratory chain, inflammatory responses and oxidative metabolism of endogenous as well as exogenous compounds are the major sources of FRs generation in humans. Reactive oxygen/nitrogen/thyil species (ROS/RNS/RSS) have been shown to be involved in all three stages of carcinogenesis (initiation-promotion-progression) (12–14). Extensive DNA damage induced by FRs can lead to mutation, alteration of phenotypic expression and cell death. Antioxidative defense system (ADS), composed of antioxidative enzymes and antioxidants, prevents biomolecules oxidative injury through FRs sequestration and reparation of already oxidatively damaged cell constituents (12, 13).

American Joint Committee on Cancer (AJCC) set up four melanoma stages based on the status of tumor thickness/size, ulceration, mitotic rate, presence of micrometastasis, tumor positive lymph nodes and distant metastasis (15).

Herein, we studied the association between OS development and melanoma stages by measuring OS parameters, including: superoxide anion radical (O$_2$•⁻), total and mitochondrial superoxide dismutase (tSOD, Mn-SOD) and catalase (CAT) activities and lipid peroxidation (LPO) by measuring malondialdehyde (MDA).

**Materials and Methods**

Consented melanoma patients were recruited from the Clinic for Dermatology and Venereology and Melanoma Center of the Military Medical Academy, Belgrade, Serbia, while healthy controls referred to healthy persons (with no prior history of cancer) on periodical systematic examinations. The study was approved by the local Research Ethics Committee, Military Medical Academy (11-03/2014).

According to the 7th edition of AJCC there are four melanoma stages: IA stage- tumors not thicker than 1.0 mm, not ulcerated, and have a mitotic rate <1 mitosis/mm$^2$; stage IB- tumors are >1.0 mm and either have at least 1 mitosis/mm$^2$ or evidence of tumor ulceration; stage IIA-ulcerated, 1.0–2.0 mm sized tumors or no ulcerated, 2.01–4.0 mm sized tumors; stage IIB-ulcerated, 2.01–4.0 mm sized tumors or no ulcerated, thicker than 4.0 mm; stage IIC-ulcerated, thicker than 4.0 mm; stage III- isolated tumor cells or tumor deposits >0.1 mm (micrometastasis, tumor positive lymph nodes) detected histopathologically or immunohistochemically; stage IV- melanomas with distant metastasis (15).

Herein, 72 melanoma patients (33 men and 39 women, mean age 54.72 ± 16.50; total melanoma patients – TMP group) were classified into three stages: initial (joined patients with IA, IB, IIA, IIB, and...
IIIC stages), middle (III melanoma stage) and final (IV melanoma stage), according to the 7th edition of AJCC melanoma classification (15). Thirty healthy controls (15 men and 15 women, mean age 50.10 ± 25.20) were recruited as control group – C group.

**Samples**

Venous blood from healthy controls and melanoma patients was collected in vacuettes with clot activator. After isolation (centrifugation at 3000 rpm for 10 minutes) serum samples were frozen at -70 °C, until testing. The activity of CAT, tSOD and Mn-SOD and levels of O$_2^-$ and MDA were analyzed.

**Determination of O$_2^-$**

Superoxide anion was determined by the reduction of nitroblue-tetrazolium (NBT) in alkaline nitrogen saturated medium (16). Kinetic analysis was performed at 550 nm on Ultrospec 2000 spectrophotometer. The results were expressed as µmol red NBT/min/L.

**Determination of t-SOD**

Superoxide dismutase (EC 1.15.1.1.; SOD) activity was measured spectrophotometrically as the inhibition of epinephrine spontaneous auto-oxidation at 480 nm (17). The kinetics of sample enzyme activity was followed in a carbonate buffer (50 mmol/L, pH 10.2) containing 0.1 mmol/L EDTA after the addition of 10 mmol/L epinephrine, on Ultrospec 2000 spectrophotometer. Data were expressed as U/mL.

**Determination of Mn-SOD**

Activity of Mn-SOD was measured at the same way as t-SOD (17) with the modification in sample amount and proceeded incubation with 25 µL of KCN (8 mmol/L) (to block Cu/Zn-SOD) for 20 min, on the room temperature.

**Determination of CAT**

Catalase (EC 1.11.1.6) activity was determined spectrophotometrically by using ammonium molybdate to produce yellow complex with H$_2$O$_2$ (18). Kinetic analysis was performed at 405 nm on Ultrospec 2000 spectrophotometer. CAT activity was defined as µmol H$_2$O$_2$ reduced per minute (µmol H$_2$O$_2$/min). Data were expressed as kU/L.

**Determination of lipid peroxidation**

Serum MDA level was measured by thiobarbituric acid reactive substances (TBARS) assay, as described by Girotti et al. (19). Two molecules of TBARS reagent (15% trichloroacetic acid + 0.375% thiobarbituric acid + 0.25 mol/L HCl) react with MDA, forming complex with absorbance measurable at 531 nm. The results were expressed as µmol/L.

**Statistical analysis**

Kolmogorov-Smirnov normality test followed by nonparametric one-way ANOVA (for multiple groups analysis) and Mann-Whitney (two groups analysis) tests were used in statistical data analysis. Spearman’s test was used to test correlation between OS parameters across melanoma stages. Statistically significant differences were considered at p<0.05. The values are expressed as means with standard error mean (SEM), since data did not follow Gaus distribution and standard deviation can not be used. Graph Pad Prism 5 software was used for data analysis. Power analysis and sample size were obtained using GPower statistical analysis program. It was calculated that total sample size is 66, based on effect size 0.4, α=0.05 (type 1 error probability), power analysis 0.8 and three groups.

**Results**

**Superoxide anion in melanoma patients**

The highest O$_2^-$ was measured in group III, though elevated values were documented in all groups: TMP (p<0.0001), I+II (p<0.0001), III (p<0.0001) and IV (p=0.0005) compared to C group (Figure 1). No significant differences were found across the groups.

**Total superoxide dismutase activity in melanoma patients**

Total SOD activity was significantly high only in III group compared to C group (p=0.0322) (Figure 2).

**Manganese superoxide dismutase activity in serum of melanoma patients**

In group IV, Mn-SOD accomplished significantly higher activity than in all other groups: I+II (p=0.0086), III (p=0.0201) and C group (p=0.0038) (Figure 3). Mn-SOD activity showed a clear increment with the disease progression.

**Catalase activity in melanoma patients**

Catalase activities in groups: TMP (p=0.0081), I+II (p=0.0269) and III (p=0.0018) were significantly higher than in C group (Figure 4). The highest CAT activity was in group III.
Figure 1 Superoxide anion radical in serum of melanoma patients: Serum $\text{O}_2^-$ levels (expressed as $\mu\text{mol red NBT/min/L}$) are presented as average (SEM). Statistically significant differences were considered at $p<0.05$. Labeling: ***$p<0.001$. Melanoma patients’ groups (according to AJCC): I+II (n=53), III (n=14) and IV (n=5). TMP- total melanoma patients (n=72), C-controls (n=30), NBT- nitroblue tetrazolium.

Figure 2 Total superoxide dismutase activity in serum of melanoma patients: Serum tSOD (sum of Cu/Zn-SOD and Mn-SOD) (U/mL) is presented as average (SEM). Statistically significant differences were considered at $p<0.05$, labeled as *. Melanoma patients’ groups (according to AJCC): I+II (n=53), III (n=14), IV (n=5). TMP- total melanoma patients (n=72) and C-controls (n=30).
Figure 3 Manganese superoxide dismutase activity in serum of melanoma patients: Serum Mn-SOD (U/mL) is presented as average (SEM). Statistically significant differences were considered at p<0.05. Labeling: *p<0.05, **p<0.01. Melanoma patients’ groups (according to AJCC): I+II (n=46), III (n=13), IV (n=4). TMP- total melanoma patients (n=63) and C-controls (n=21).

Figure 4 Catalase activity in serum of melanoma patients: Serum CAT (kU/L) is presented as average (SEM). Statistically significant differences were considered at p<0.05. Labeling: *p<0.05, **p<0.01. Melanoma patients’ groups (according to AJCC): I+II (n=53), III (n=14) and IV (n=5). TMP- total melanoma patients (n=72) and C-controls (n=30).
Figure 5 Lipid peroxidation in serum of melanoma patients: Lipid peroxidation (μmol MDA/L) is presented as average (SEM). Statistically significant differences were considered at p<0.05. Labeling: *p<0.05, **p<0.01, ***p<0.001. Melanoma patients’ groups (according to AJCC): I+II (n=53), III (n=14) and IV (n=5). TMP: total melanoma patients (n=72) and C-controls (n=30).

Table I Correlation between OS parameters in early melanoma stage.

|          | Correlations: I+II stage |
|----------|--------------------------|
|          | O₂⁻⁻ | MDA | CAT | t-SOD | Mn-SOD |
| O₂⁻⁻    |      |     |     |       |       |
| r        | 1.000 | 0.177 | -0.491** | -0.359** | -0.292* |
| p        | –     | 0.206 | 0.000 | 0.008 | 0.049 |
| N        | 53    | 53    | 53    | 53    | 46    |
| MDA      |      |     |     |       |       |
| r        | 0.177 | 1.000 | -0.134 | 0.037 | 0.044 |
| p        | 0.206 | –     | 0.338 | 0.792 | 0.772 |
| N        | 53    | 53    | 53    | 53    | 46    |
| CAT      |      |     |     |       |       |
| r        | -0.491** | -0.134 | 1.000 | 0.570** | 0.366* |
| p        | 0.000 | 0.338 | –     | 0.000 | 0.012 |
| N        | 53    | 53    | 53    | 53    | 46    |
| t-SOD    |      |     |     |       |       |
| r        | -0.359** | 0.037 | 0.570** | 1.000 | 0.393** |
| p        | 0.008 | 0.792 | 0.000 | –     | 0.007 |
| N        | 53    | 53    | 53    | 53    | 46    |
| Mn-SOD   |      |     |     |       |       |
| r        | -0.292* | 0.044 | 0.366* | 0.393** | 1.000 |
| p        | 0.049 | 0.772 | 0.012 | 0.007 | –     |
| N        | 46    | 46    | 46    | 46    | 46    |

Spearman’s correlation was used to test OS parameters association with melanoma stage. Two tailed test Spearman’s correlation was performed. Labeling: number of patients – N; Correlation coefficient – r; Statistical significance – p (*p<0.05, **p<0.01)
Malondialdehyde values in melanoma patients

Lipid peroxidation, expressed as a MDA, was significantly elevated in TMP (p=0.0008), I+II (p=0.0058), III (p=0.0050) and IV (p=0.0033) compared to controls (Figure 5). Patients in group IV had significantly higher MDA than in group I+II (p=0.0282) and III (p=0.0299). The highest MDA was in group IV.

Correlations between parameters of OS

Negative correlation between O$_2$•$^-$ and CAT, O$_2$•$^-$ and tSOD, O$_2$•$^-$ and Mn-SOD; and positive between CAT and tSOD, CAT and Mn-SOD, tSOD and Mn-SOD were obtained in early stage of disease (I+II) (Table I), while no correlation was obtained in the middle and later stages (III+IV).

Discussion

Cutaneous malignant melanoma develops in three different stages, from radial to vertical growth phases and metastatic disease. Clinically, radial growth phase presents as patches or plaques, this is an early melanoma stage (stage I+II, according to the AJCC). Melanoma cells show radial spread, usually confined to the intra-epidermal compartment, while melanoma’s mitosis are frequently seen in the epidermis but rarely in the dermis (20). Vertical growth phase of melanoma refers to gray-black, blue-black or even amelanotic nodules and is classified as an early and/or a late stage (stage III, according to the AJCC). In an early stage, a small papulonodule arises in a radial growth phase lesion and is usually darker than radial growth phase associated lesions, whereas in a late or developed vertical may be present and tumor aggregates may extend into the reticular dermis or even subcutaneous fat (20). The terminal phase of melanoma progression assumes distant metastasis expansion (stage IV, according to the AJCC).

Positive association between OS and clinical stages of melanoma progression is confirmed by our study. Oxidative stress-associated diseases, including melanoma, underline cross-reactions between over-produced FRs and immune responses, in humans (21–25). Regulatory mechanisms of OS on tumor growth and progression comprise genomic instability, oncogene activation and angiogenesis (26). It was shown that ROS alter proto-oncogene B-Raf that encodes B-Raf protein (BRAF), a known activator of oncogenic (37).

Increased activity of CAT in TMP suggests a pivotal role of this enzyme against OS. The higher SOD and CAT activities, seen in melanoma patients, correspond to ROS overproduction (increased O$_2$•$^-$) and oncopgenes such as c-fos, c-jun and c-myc, that leads to cell proliferation and blocking of apoptosis (29, 30). Notable, ROS promote many aspects of tumor development and progression including: (a) cellular proliferation e.g. extracellular-regulated kinase 1/2 (ERK1/2) activation; (b) evasion of apoptosis e.g. Src, NF-B and phosphatidylinositol-3 kinase (PI3K)/Akt activation; (c) tissue invasion and metastasis e.g. metalloproteinase(MMP) secretion into the extracellular matrix (ECM); and (d) angiogenesis e.g. release of vascular endothelial growth factor (VEGF) and angiopoietin (31).

Overproduction of ROS is necessary but not sufficient to induce malignancy. Free radicals readily attack all classes of biomolecules (proteins, DNA, unsaturated fatty acids) and cause toxic and/or mutagenic effects. In reaction with DNA, ROS induce base-oxidation and deamination, base loss, single and double-strand breaks, crosslinks, deletion, mutation, translocation. The consequences of oxidatively damaged DNA are transcription blockage, replication errors and genomic instability, which is the first step in process of mutagenesis, carcinogenesis and aging (32). Deteriorated protein's primary structure by ROS causes modification and loss of some amino acids, formation of S-S bridges and carbonyl groups, aggregation and fragmentation, increased proteolytic sensitivity, loss of catalytic function and changes in secondary and tertiary protein structure, affecting their viscosity and charge (33). Changed secondary and tertiary protein structure can induce cell death. Protonated O$_2$•$^-$ form, perhydroxyl radical (H$O_2$•$^-$, pKa=4.7) can abstract bis-allylic H+ from poly unsaturated fatty acids (PUFA) and triggers LPO, unlike O$_2$•$^-$ itself. Hydrogen peroxide produced in the reaction of O$_2$•$^-$ dismutation by SOD, easily diffuses through cellular membranes and precedes the production of the most potent hydroxyl radical (HO$^*$) by its homolytic cleavage or through Fenton reaction. Conversion of H$_2$O$_2$ into water is catalyzed by CAT primarily and glutathione peroxidase (GPx). If the production of H$_2$O$_2$ overwhelms the activity of CAT and GPx, it can participate in Fenton-like reactions together with transitional metals, such as Fe$^{2+}$ or Cu$^{1+}$, giving rise to toxic HO$^*$ that imposes mutagenic effect in reaction with DNA (34). Initiation, propagation and termination of LPO comprise the formation of PUFA radical (PUFA$^*$), alkyl peroxyl (PUFA-OO$^*$), alkoxy (PUFA-O$^*$) and alkyl hydroperoxides (PUFA-OOH), which undergo-scission reactions or intramolecular cyclisation, followed by the decomposition into carbonyls (including MDA) (35, 36). Malondialdehyde is highly cytotoxic and it has been confirmed as a potent enzymes inhibitor, tumor promoter and co-carcinogenic (37).
LPO (increased MDA), confirming that melanoma is OS-associated disease (38).

Redox status differs across body organs/tissues due to anatomical, blood supply status and other specificities (25). Sander et al. (39) reported on significantly elevated antioxidant enzymes (CAT, SOD) activity and MDA level in malignant tissues of melanoma patients. They were the first who found the correlation between melanoma and MDA in human skin in vivo.

Schadendorf et al. (40) reported on statistically elevated serum Mn-SOD activity in all clinical stages of melanoma, compared with controls (p < 0.005), while in our study Mn-SOD activity was significantly higher only in stage IV compared with control group (Figure 3).

In line with our results regarding OS development in melanoma patients are findings of other authors. Accordingly, Gadjeva et al. (22) documented significant increase of plasma MDA and CAT activity in melanoma patients, as we found too, but significantly low CuZn-SOD activity if compared with healthy controls. Interestingly, they showed that plasma MDA levels decreased after the surgery (removal of melanoma tissues) indicating melanoma tissue as a significant FRs producer, though activities of SOD and CAT remained the same, as before the surgery. Mantovani et al. (41) emphasized that OS development is associated with insufficient antioxidative capacity in different types of cancer, reporting on ROS overproduction, significantly elevated serum Mn-SOD activity in all clinical stages of melanoma, compared with controls (p < 0.005), and for better understanding the role of OS in melanoma progression.

The main limitation of this study include small number of melanoma patients in late melanoma stage (IV group), that is expected because of high mortality rate.

**Conflict of interest statement**

The authors declare that they have no conflicts of interest for this work.

**References**

1. Bandarchi B, Ma L, Navab R, Seth A, Rasty G. From melanocyte to metastatic malignant melanoma. Dermatol Res Pract 2010; 2010: 583748.

2. Stanojević I, Gavević M, Jović M, Mijušković Z, Zevević R, Zolatarevski L et al. Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients. Vojnosanit Pregl 2015; 72(4): 342–9.

3. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12(1): 20–37.

4. Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl 2013; 11(2): 81–91.

5. Zhang Z, Zhu S, Yang Y, Ma X, Guo S. Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness. Tumour Biol 2015; 36(11): 8593–600.

6. Swetter SM, Clarke CA, Keegan THM. Why Do Men Have Worse Melanoma Survival than Women? Is It Behavior, Biology, or Both? The Melanoma Letter Summer 2014; 32(2): 4–6.

7. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for melanoma: a meta-analysis of pigmentary characteristics and freckling. Int J Cancer 2010; 127(10): 2430–45.

8. Williams PF, Olsen CM, Hayward NK, Whiteman DC. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis of tumourigenic characteristics and freckling. Int J Cancer 2011; 129(7): 1730–40.

9. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevid. Eur J Cancer 2005; 41(1): 28–44.

10. Olsen CM, Carroll HJ, Whiteman DC. Estimating the attributable fraction for cancer: A meta-analysis of new and melanoma. Cancer Prev Res (Phila) 2010; 3(2): 235–45.

11. Denat L, Kadekar AL, Marrot L, Leachman SA, Abdel-Malek ZA. Melanocytes as instigators and victims of oxidative stress. J Investig Dermatol 2014; 134(6): 1512–8.
12. Djukic M, Ninkovic M, Jovanovic M. Oxidative stress – clinical diagnostic significance. J Med Biochem 2008; 27(4): 409–425.
13. Li YR, Jia Z, Trush MA. Defining ROS in biology and medicine. Reactive Oxygen Species 2016; 1(1): 9–21.
14. Liou GY, Storz P. Reactive oxygen species in cancer. Free Radic Res 2010; 44(5): 479–96.
15. Balch CM, Gershewald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27(36): 6199–206.
16. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenwald RA, editor. Handbook of Methods for Oxygen Radical Research, 5th ed. Florida: CRC Press, 1985: 123–52.
17. Sun M, Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 1978; 90(1): 81–9.
18. Göth L. A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 1991; 196(2–3): 143–51.
19. Girotti MJ, Khan N, McLellan BA. Early measurement of systemic lipid peroxidation products in the plasma of major blunt trauma patients. J Trauma 1991; 31(1): 32–5.
20. Slominski A, Wortsman J, Carlson A, Matsuoka L, Balch CM, Mihm M. Malignant melanoma: An update. Arch Pathol Lab Med 2001; 125: 1295–306.
21. De Cavanagh EM, Honegger AE, Hofer E, Bordenave C, Mihm M. Malignant melanoma: An update. Arch Pathol Lab Med 2001; 125: 1295–306.
22. De Cavanagh EM, Honegger AE, Hofer E, Bordenave C, Mihm M. Malignant melanoma: An update. Arch Pathol Lab Med 2001; 125: 1295–306.
23. Gupta A, Bhatt ML, Misra MK. Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev 2009; 2(2): 68–72.
24. Djukic M, Djukic M, editor. Oksidativni stres – klini~ko-dijagnosti~ki zna~aj. Belgrade: Mono i Manjana, 2008.
25. Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat 2012; 133(3): 881–8.
26. Djukić M, editor. Oksidativni stres – kliničko-dijagnostički značaj. Beograd: Mono i Manjana, 2008.
27. Bošnjak M, Djukić M. Oxidative stress markers and melanoma. Pigment Cell Melanoma Res 2010; 23(3): 352–64.
28. Halliwell B. Oxidative stress and cancer: have we moved forward? Biochem J 2007; 401(1): 1–11.